Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases

Research collaboration combines Amplitude's proprietary taRNA with Lilly's global development, manufacturing, and commercialization capabilities Initial programs target infectious diseases with high unmet need, with Lilly retaining options for up to two additional targets BOSTON, Aug. 19,...